-
1
-
-
7444236094
-
-
Li Y B, Weng J P, Chen X H, et al. Chin J Diabetes, 2003, 11(1):10-15
-
(2003)
Chin J Diabetes
, vol.11
, Issue.1
, pp. 10-15
-
-
Li, Y.B.1
Weng, J.P.2
Chen, X.H.3
-
2
-
-
67649493349
-
-
Li H Z, Wang M, Liu X H, et al. J Chin Physician, 2004, 6(1): 82-83
-
(2004)
J Chin Physician
, vol.6
, Issue.1
, pp. 82-83
-
-
Li, H.Z.1
Wang, M.2
Liu, X.H.3
-
3
-
-
0027360243
-
Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipo-protein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects
-
Uusitupa M I, Niskanen L K, Siitonen O, et al. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipo-protein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia, 1993, 36(11): 1175-1184
-
(1993)
Diabetologia
, vol.36
, Issue.11
, pp. 1175-1184
-
-
Uusitupa, M.I.1
Niskanen, L.K.2
Siitonen, O.3
-
4
-
-
0032036510
-
How should we respond to the worldwide diabetes epidemic
-
Clark C M Jr. How should we respond to the worldwide diabetes epidemic. Diabetes Care, 1998, 21(4): 475-476
-
(1998)
Diabetes Care
, vol.21
, Issue.4
, pp. 475-476
-
-
Clark Jr., C.M.1
-
5
-
-
0031965011
-
Diabetic retinopathy
-
Aiello L P, Gardner T W, King G L, et al. Diabetic retinopathy. Diabetes Care, 1998, 21(1): 143-156
-
(1998)
Diabetes Care
, vol.21
, Issue.1
, pp. 143-156
-
-
Aiello, L.P.1
Gardner, T.W.2
King, G.L.3
-
7
-
-
0029989710
-
Drug therapy of non-insulin-dependent diabetes mellitus in the elderly
-
Mooradian A D. Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Drugs, 1996,51(6): 931-941
-
(1996)
Drugs
, vol.51
, Issue.6
, pp. 931-941
-
-
Mooradian, A.D.1
-
8
-
-
0030826933
-
Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments
-
8ScheenAJ.Drugtreatmentofnon-insulin-dependentdiabetesmellitusinthe1990s. Achievementsandfuturedevelopments.Drugs,1997,54(3):355-368(Pubitemid27395588)
-
(1997)
Drugs
, vol.54
, Issue.3
, pp. 355-368
-
-
Scheen, A.J.1
-
9
-
-
33750587755
-
Fibroblast growth factor-21 improves pancreatic-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and akt signaling pathways
-
Wente W, Efanov A M, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and akt signaling pathways. Diabetes, 2006, 55(9): 2470-2478
-
(2006)
Diabetes
, vol.55
, Issue.9
, pp. 2470-2478
-
-
Wente, W.1
Efanov, A.M.2
Brenner, M.3
-
10
-
-
33846418834
-
The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
-
Kharitonenkov A, Wroblewski V J, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 2007, 148(2): 774-781
-
(2007)
Endocrinology
, vol.148
, Issue.2
, pp. 774-781
-
-
Kharitonenkov, A.1
Wroblewski, V.J.2
Koester, A.3
-
11
-
-
20444435873
-
FGF-21 as a novel metabolic regulator
-
Kharitonenkov A, Shiyanova T L, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest, 2005, 115(6): 1627-1635
-
(2005)
J Clin Invest
, vol.115
, Issue.6
, pp. 1627-1635
-
-
Kharitonenkov, A.1
Shiyanova, T.L.2
Koester, A.3
-
12
-
-
29344475982
-
Comparison of SUMO fusion technology with traditional gene fusion systems: Enhanced expression and solubility with SUMO
-
Marblestone J G, Edavettal S C, Lim Y, et al. Comparison of SUMO fusion technology with traditional gene fusion systems: Enhanced expression and solubility with SUMO. Protein Science, 15(1): 182- 189
-
Protein Science
, vol.15
, Issue.1
, pp. 182-189
-
-
Marblestone, J.G.1
Edavettal, S.C.2
Lim, Y.3
-
13
-
-
0017637022
-
Cleavage at Asn-Gly bonds with hydroxylamine
-
Part E
-
Bornstein P, Balian G. Cleavage at Asn-Gly bonds with hydroxylamine. Meth Enzy-Mol, 1997, 47(Part E): 132-145
-
(1997)
Meth Enzy-Mol
, vol.47
, pp. 132-145
-
-
Bornstein, P.1
Balian, G.2
-
14
-
-
0004136246
-
Mogecular Cloning
-
2nd. New York: Cold Spring Harbor Labo- ratary Press
-
Sambrook J, FritschEF, Manutus T. Mogecular Cloning, A Laboratory Manual, 2nd. New York: Cold Spring Harbor Labo- ratary Press, 1989. 9880-9898
-
(1989)
A Laboratory Manual
, pp. 9880-9898
-
-
Sambrook, J.1
Fritsch, E.F.2
Manutus, T.3
-
15
-
-
0003855149
-
-
3rd. Boston: John Wiley&Sons, Inc
-
Ausubel F M, Brent R, Kingston R E, et al. Short Protocols in Molecular Biology, 3rd. Boston: John Wiley&Sons, Inc, 1992. 652-658
-
(1992)
Short Protocols in Molecular Biology
, pp. 652-658
-
-
Ausubel, F.M.1
Brent, R.2
Kingston, R.E.3
-
16
-
-
23244434197
-
SUMO fusion technology for difficult-to-express proteins
-
Butt T R, Edavettal S C, Hall J P, et al. SUMO fusion technology for difficult-to-express proteins. Protein Expr Purif, 43(1): 1-9
-
Protein Expr Purif
, vol.43
, Issue.1
, pp. 1-9
-
-
Butt, T.R.1
Edavettal, S.C.2
Hall, J.P.3
-
17
-
-
20444419709
-
Enhanced expression and purification of membrane proteins by SUMO fusion in escherichia coli
-
DOI 10.1007/s10969-005-2664-4
-
Zuo X, Li S, Hall J, et al. Enhanced expression and purification of membrane proteins by SUMO fusion in Escherichia coli. J Struct Funct Gen, 2005, 6(2-3): 103-111 (Pubitemid 41428117)
-
(2005)
Journal of Structural and Functional Genomics
, vol.6
, Issue.2-3
, pp. 103-111
-
-
Zuo, X.1
Li, S.2
Hall, J.3
Mattern, M.R.4
Tran, H.5
Shoo, J.6
Tan, R.7
Weiss, S.R.8
Butt, T.R.9
-
18
-
-
0031960061
-
Troglitazone in type II diabetes mellitus
-
Sparano N, Seaton T L. Troglitazone in type II diabetes mellitus. Pharmacotherapy, 1998, 18(3): 539-548
-
(1998)
Pharmacotherapy
, vol.18
, Issue.3
, pp. 539-548
-
-
Sparano, N.1
Seaton, T.L.2
-
19
-
-
0032568257
-
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
-
Inzucchi S E, Maggs D G, Spollett G R, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med, 1998,338(13): 867-872
-
(1998)
N Engl J Med
, vol.338
, Issue.13
, pp. 867-872
-
-
Inzucchi, S.E.1
Maggs, D.G.2
Spollett, G.R.3
-
20
-
-
0030020965
-
Metformin: An antihyperglycemic agent for treatment of type II diabetes
-
Melchior W R, Jaber L A. Metformin: an antihyperglycemic agent for treatment of type II diabetes. Ann Pharmacother, 1996, 30(2): 158-164
-
(1996)
Ann Pharmacother
, vol.30
, Issue.2
, pp. 158-164
-
-
Melchior, W.R.1
Jaber, L.A.2
-
21
-
-
0029914136
-
Acarbose: Its role in the treatment of diabetes mellitus
-
21CampbellLK,WhiteJR,CampbellRK,Acarbose: itsroleinthetreatmentofdiabetesme-llitus.AnnPharmacother,1996,30(11): 1255-1262(Pubitemid26367448)
-
(1996)
Annals of Pharmacotherapy
, vol.30
, Issue.11
, pp. 1255-1262
-
-
Campbell, L.K.1
White, J.R.2
Campbell, R.K.3
-
22
-
-
67649541742
-
-
Ren G P, Li L, Sun G P, et al. Prog Biochem Biophys, 2009, 36(2): 165-174
-
(2009)
Prog Biochem Biophys
, vol.36
, Issue.2
, pp. 165-174
-
-
Ren, G.P.1
Li, L.2
Sun, G.P.3
-
23
-
-
43549110007
-
FGF21 attenuates lipolysis in human adipocytes-A possible link to improved insulin sensitivity
-
Arnera P, Pettersson A, Mitchell P J, et al. FGF21 attenuates lipolysis in human adipocytes-A possible link to improved insulin sensitivity. FEBS Letters, 2008, 582: 1725-1730
-
(2008)
FEBS Letters
, vol.582
, pp. 1725-1730
-
-
Arnera, P.1
Pettersson, A.2
Mitchell, P.J.3
-
24
-
-
20444400305
-
Expression and purification of SARS Coronavirus proteins using SUMO fusions
-
Zuo X, Mattern M R, Tan R, et al. Expression and purification of SARS Coronavirus proteins using SUMO fusions. Protein Expr Purif, 42(1): 100-110
-
Protein Expr Purif
, vol.42
, Issue.1
, pp. 100-110
-
-
Zuo, X.1
Mattern, M.R.2
Tan, R.3
-
25
-
-
3543073550
-
SUMO fusions and SUMO-specific protease for efficient expression and purifycation of proteins
-
Malakhov M P, Mattern M R, Malakhov O A, et al. SUMO fusions and SUMO-specific protease for efficient expression and purifycation of proteins. J Struct Funct Gen, 2004, 5(1-2): 75-86
-
(2004)
J Struct Funct Gen
, vol.5
, Issue.1-2
, pp. 75-86
-
-
Malakhov, M.P.1
Mattern, M.R.2
Malakhov, O.A.3
|